TrialCancer2009

A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer.

Edward S Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.